Skip to content

A CD44-regulating Multimodal Therapeutic Strategy for MAFLD-Associated Pancreatic Cancer Liver Metastasis.

Nov 2026 · Cancer Letters · pp. 218954 · 0 citations · 56 references
Medicine

Abstract

Metabolic dysfunction-associated fatty liver disease (MAFLD) has emerged as a novel risk factor for pancreatic cancer, particularly early liver metastasis. However, the underlying mechanisms and effective therapeutic strategies remain largely unclear. Here, based on clinical databases, patient tissue samples, and single-cell sequencing of mouse models, we identified CD44 as a key contributor to MAFLD-associated pancreatic cancer progression. High CD44 expression was significantly associated with poor survival in patients with pancreatic cancer and was further elevated in MAFLD-associated liver metastatic lesions. Considering that the limited effects of single treatment, we developed a cationic DOTAP/cholesterol liposomal nanoplatform co-loaded with gemcitabine, IR780, and CD44 siRNA (GIR@Lip) for combined chemotherapy, photothermal therapy, and immunotherapy. GIR@Lip nanoparticles exhibited excellent size uniformity, stability, and photothermal conversion efficiency, which could efficiently inhibit KPC cells' viability, migration and invasion, downregulate CD44 expression and stimulate immune response. Furthermore, GIR@Lip efficiently accumulated in tumor tissues in vivo, exhibiting a significant reduction in liver metastatic lesions and remodeling the M1 type tumor associated macrophages (TAMs), CD4+ and CD8+ T cells. Collectively, these findings identify CD44 as a potential therapeutic target for MAFLD-associated pancreatic cancer liver metastasis and highlight GIR@Lip as a promising multimodal strategy for its treatment.

View source

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.